This activity is supported by an educational grant from AstraZeneca.
Friday, November 6, 2015
1:30 PM - 3:00 PM
New York Marriott Marquis
Sky Lobby, Level 16
New York, NY 10036
This activity aims to update oncology healthcare professionals who participate in the multidisciplinary treatment of patients with lung cancers by providing expert guidance, interpretation, and opinions on the importance and impact of EGFR and molecular testing through multiple lines of therapy, as well as emerging technologies that can assist in this regard.
This will be a 3-module Medical Crossfire® panel discussion, highlighting the expert exchange of ideas and best practices regarding the impact of mutational testing throughout the lung cancer treatment paradigm. Module 1 will be mostly didactic in nature, with discussion of needs and ways to overcome barriers to optimal testing. Modules 2 and 3 will be case-based discussions and interpretations in the setting of EGFR mutated NSCLC along the continuum of disease.
This educational activity is directed toward medical oncologists, pulmonologists, pathologists, and radiologists who treat patients with lung cancer. Nurse practitioners, nurses, physician assistants, pharmacists, researchers, and other healthcare professionals interested in the treatment of lung cancer may also participate.
After successful completion of this educational activity, participants should be able to:
It is the policy of PER® to ensure balance, independence, objectivity, and scientific rigor in all of its educational activities. In accordance with the ACCME Standards for Commercial SupportSM, PER® requires everyone who is in a position to control the content of an educational activity, including spouses/partners, to disclose all relevant financial relationships with any commercial interest. PER® has implemented mechanisms to identify and resolve all conflicts of interest prior to the start of each activity. Participants are notified prior to the activity of the presence or absence of relevant financial relationships between faculty and commercial interests. Information disclosed includes the name of the faculty, nature of the relevant financial relationship (eg, member of speakers bureau, grant/research support, consulting arrangement), and the name of the company/organization with which the relationship exists. Additionally, prior to the start of each activity PER® discloses the source of commercial support AstraZeneca to the participants.
The following individuals have no relevant financial relationships with commercial interests to disclose:
The staff of Physicians’ Education Resource®, LLC
The following individuals have relevant financial relationships with commercial interests to disclose:
Mark G. Kris, MD - Grant/Research Support: Puma Biotechnology, Pfizer, Genentech; Consultant: AstraZeneca, ARIAD Pharmaceuticals, Roche/Genentech, Array; Benjamin P. Levy, MD - Consultant: Genentech, Eli Lilly, AstraZeneca, Celgene Corporation, Biodesix; Speakers Bureau: Genentech; Gregory Riely, MD, PhD - Grant/Research Support: Roche, Novartis, Pfizer, Infinity, GlaxoSmithKline, Millennium: The Takeda Oncology Company; Consultant: Novartis; Heather Wakelee, MD - Grant/Research Support: Novartis, Bristol-Myers Squibb, Clovis Oncology, Xcovery, Celgene Corporation, Roche/Genentech, MedImmune, Pfizer, Lilly; Consultant: Peregrine Pharmaceuticals, Novartis, ACEA Biosciences
This CME activity may or may not discuss investigational, unapproved, or off-label use of drugs. Participants are advised to consult prescribing information for any products discussed. The information provided in this CME activity is for continuing medical education purposes only, and is not meant to substitute for the independent medical judgment of a physician relative to diagnostic and treatment options for a specific patient’s medical condition.
The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER®.
*Information accurate at time of posting
PER® complies with the Physician Payments Sunshine Act as a part of the Affordable Care Act (ACA). Accordingly, PER® may be required to collect information on transfers of value provided to any covered recipient under the ACA.
March 7, 2019 - March 10, 2019
March 8, 2019
Cancer Summaries and Commentaries™: Update from Atlanta – Advances in the Treatment of Acute Myeloid Leukemia
Mar 30, 2019
Mar 30, 2019
Mar 30, 2019